Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR

What Was Tested

This clinical trial paper looks at Octreotide.

To evaluate the GH isoforms (20kDa- and 22kDa-hGH) in acromegalic patients before and after six months of treatment with octreotide LAR, and to compare the results with those in healthy controls.

In addition, the relationships between the %20kDa-hGH, tumor size and biochemical measurements were also investigated.

Why It Was Studied

Human growth hormone (hGH) circulates as a mixture of different isoforms.

Who Took Part

The abstract describes 23 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

Growth hormone, IGF-I and prolactin (PRL) were measured by chemiluminescence immunometric assay and the 20kDa- and 22kDa-hGH isoforms were measured by specific time-resolved fluorescence immunoassays.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Adenoma, Case-Control Studies, Chemotherapy, Adjuvant, Fluoroimmunoassay, Growth Hormone-Secreting Pituitary Adenoma and Human Growth Hormone.

What This Means in Plain Language

This is a clinical trial of Octreotide in 23 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Octreotide compound page, all human trials.